Expanded Access for Apixaban
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
This is an expanded access designed to provide access to apixaban for eligible participants.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 16, 2021
CompletedFirst Posted
Study publicly available on registry
January 11, 2022
CompletedMarch 18, 2022
March 1, 2022
November 16, 2021
March 7, 2022
Interventions
Eligibility Criteria
You may qualify if:
- Pediatric patients with Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention
- Previously participated in the CV185-362 study and was on apixaban for 1 year or until treatment was no longer required
You may not qualify if:
- Weight less than 5 kg or greater than 35 kg
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Childrens Hospital Of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Related Links
MeSH Terms
Interventions
Study Officials
- STUDY DIRECTOR
Bristol-Myers Squibb
Bristol-Myers Squibb
Central Study Contacts
Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 16, 2021
First Posted
January 11, 2022
Last Updated
March 18, 2022
Record last verified: 2022-03